Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation has released its financial results for the first half of 2024, highlighting business achievements of its listed subsidiary, Legend Biotech Corporation. Legend Biotech, trading on the Nasdaq via American Depositary Shares, has submitted its half-year unaudited financials and product pipeline updates to the SEC. Investors are reminded to exercise caution and consider the potential risks before trading in the company’s securities.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
